WASHINGTON UNIVERSITY INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES

华盛顿大学临床与转化科学研究所

• 批准号: 8173739
• 负责人: KENNETH S POLONSKY
• 金额: $ 421.83万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-06-01 至 2011-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8173739
• 关键词: Clinical; Institutes; Translational Research; Universities; Washington

This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. This CTSA application from Washington University in St. Louis (WU) is built on a long institutional history of outstanding biomedical research, research training, and patient care. WU is the recipient of the 4 clinical research and training grants that form the basis of the CTSA (GCRC, currently in its 46th year of funding, and K12, K30, and T32 grants.) Another critical element is WU's new BioMed 21 strategic initiative in multidisciplinary, collaborative research in genome sciences, biological imaging, and clinical investigation. All these elements will be conjoined with other existing resources at WU to form a transformational new Institute of Clinical and Translational Sciences (ICTS). By implementing the 15 key Program Functions described in this application, the ICTS will conceptually and operationally reinvent and reinvigorate clinical and translational research and clinical research training at WU. An unprecedented level of partnership with other academic, healthcare, community and scientific institutions that complement our core expertise in laboratory and clinical research and research training is central to the transformation that will be led by the ICTS. Our partners include BJC HealthCare, an integrated academic and community health care delivery system; Saint Louis University School of Public Health, Graduate School and Doisy College of Health Sciences; University of Missouri St. Louis College of Nursing; Southern Illinois University Edwardsville School of Nursing; and St. Louis College of Pharmacy; key organizations promoting community health as well as biomedical and pharmaceutical companies in the St. Louis area. The coupling of these resources creates an outstanding environment to make basic laboratory discoveries that can then be translated into clinical research protocols and ultimately into advances in clinical practice and patient care through extensive community interactions and commercial partnerships." To ensure the success of the ICTS, WU has made substantial commitments of space and financial support. Barnes-Jewish and St. Louis Children's Hospitals, our academic hospital-partnersrand-BdC HealthCare, our affiliated health system, have also made substantial commitments to the clinical research activities of the ICTS. These additional resources coupled with the existing high quality programs in clinical and translational science ensure that WU will make outstanding contributions to this NIH initiative.

该子项目代表了 CTSA 资金百分比的估计 被用于广泛的研究领域（艾滋病研究、儿科研究或 临床试验）。 列出的总成本只是 CTSA 金额的估计值 该研究领域的基础设施，而不是直接资助 NCRR 向子项目或子项目人员提供的补助金。 圣路易斯华盛顿大学 (WU) 的 CTSA 申请建立在杰出生物医学研究、研究培训和患者护理的悠久机构历史之上。西弗吉尼亚大学是构成 CTSA 基础的 4 项临床研究和培训资助的获得者（GCRC，目前已进入第 46 个资助年头，以及 K12、K30 和 T32 资助）。另一个关键因素是西西兰大学的新 BioMed 21 战略计划从事基因组科学、生物成像和临床研究的多学科合作研究。所有这些要素将与西弗吉尼亚大学的其他现有资源相结合，形成一个变革性的新临床和转化科学研究所 (ICTS)。通过实施本申请中描述的 15 项关键计划功能，ICTS 将在概念上和操作上重塑并重振 WU 的临床和转化研究以及临床研究培训。与其他学术、医疗保健、社区和科学机构建立前所未有的合作伙伴关系，补充我们在实验室和临床研究以及研究培训方面的核心专业知识，对于 ICTS 领导的转型至关重要。我们的合作伙伴包括 BJC HealthCare，一个综合学术和社区医疗保健服务系统；圣路易斯大学公共卫生学院、研究生院和多伊西健康科学学院；密苏里大学圣路易斯护理学院；南伊利诺伊大学爱德华兹维尔护理学院；和圣路易斯药学院；促进社区健康的主要组织以及圣路易斯地区的生物医学和制药公司。这些资源的结合创造了一个出色的环境，可以进行基本的实验室发现，然后可以将其转化为临床研究方案，并最终通过广泛的社区互动和商业伙伴关系转化为临床实践和患者护理的进步。” WU 为我们的学术医院合作伙伴 Barnes-Jewish 和圣路易斯儿童医院以及我们的附属卫生系统 BdC HealthCare 做出了实质性的空间和财政支持承诺，也为我们的临床研究活动做出了实质性的承诺。 ICTS。这些额外资源加上现有的高质量临床和转化科学项目，确保 WU 将为 NIH 的这项举措做出杰出贡献。